Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all?

Leuk Lymphoma. 2016 May;57(5):987-90. doi: 10.3109/10428194.2016.1164858.

Authors

Paula Cramer¹, Petra Langerbeins¹, Kirsten Fischer¹, Barbara Eichhorst¹, Michael Hallek^{1

2}, Valentin Goede^{1

3}

Affiliations

¹ a Department I of Internal Medicine , Center of Integrated Oncology Cologne-Bonn and German CLL Study Group, University of Cologne , Cologne , Germany ;
² b CECAD - Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases , Cologne , Germany ;
³ c Department of Geriatric Medicine , St. Marien Hospital , Cologne , Germany.

PMID: 27096890
DOI: 10.3109/10428194.2016.1164858

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cyclophosphamide / therapeutic use*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Rituximab

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Rituximab
Cyclophosphamide